
Michał Biśta, PhD
Co-founder & CEO
Former Vice President of Structure, Fragments and Biophysics at Captor Therapeutics. Worked in drug discovery at AstraZeneca and in protein research at the MRC Laboratory of Molecular Biology and the Max Planck Institute of Biochemistry.
At AstraZeneca, contributed to the discovery of saruparib (AZD5305), a small-molecule PARP1 inhibitor being evaluated in multiple Phase 3 trials.
Strategy and drug discovery experience







